Cara Therapeutics (CARA) Earns News Sentiment Rating of 0.18
News stories about Cara Therapeutics (NASDAQ:CARA) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cara Therapeutics earned a coverage optimism score of 0.18 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 45.645313255264 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the news articles that may have effected Accern Sentiment Analysis’s analysis:
- Wizard World : Announces Partnership With China’s CNLive to Provide English Language Programming Across Mainland China (4-traders.com)
- Cara Therapeutics, Inc. (CARA) stands -5.61% away from 50 SMA: Technical Watch – Voice Of Analysts (analystsbuzz.com)
- Wizard World : Wizardworld-ComicCon nails it in nashville again (4-traders.com)
- Cara Therapeutics Inc (NASDAQ:CARA) Fails To Extend Gains – MMJ Reporter (mmjreporter.com)
- Neuropathic Pain – Pipeline Review, H1 2017 Market Report; Launched via MarketResearchReports.com (sbwire.com)
A number of analysts recently commented on the company. Stifel Nicolaus reiterated a “buy” rating and set a $20.00 price objective (down previously from $24.00) on shares of Cara Therapeutics in a research report on Friday, June 23rd. Vetr upgraded Cara Therapeutics from a “buy” rating to a “strong-buy” rating and set a $22.99 price objective for the company in a research report on Tuesday, July 4th. Raymond James Financial, Inc. reduced their price objective on Cara Therapeutics from $28.00 to $25.00 and set a “market perform” rating for the company in a research report on Thursday, August 3rd. Piper Jaffray Companies set a $27.00 price objective on Cara Therapeutics and gave the company a “buy” rating in a research report on Saturday, August 5th. Finally, HC Wainwright reiterated a “buy” rating and set a $30.00 price objective on shares of Cara Therapeutics in a research report on Friday, August 4th. Four analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $25.50.
Shares of Cara Therapeutics (NASDAQ CARA) traded down 0.91% during mid-day trading on Friday, reaching $13.06. The company’s stock had a trading volume of 648,304 shares. The firm’s market cap is $425.51 million. Cara Therapeutics has a 12-month low of $5.85 and a 12-month high of $28.50. The firm’s 50-day moving average price is $13.67 and its 200 day moving average price is $16.08.
Cara Therapeutics (NASDAQ:CARA) last announced its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.61) by $0.32. During the same period in the previous year, the business posted ($0.48) earnings per share. The business’s revenue was down 100.0% compared to the same quarter last year. On average, analysts expect that Cara Therapeutics will post ($1.78) EPS for the current year.
In related news, VP Frederique Ph.D. Menzaghi sold 3,000 shares of Cara Therapeutics stock in a transaction dated Friday, July 14th. The stock was sold at an average price of $15.00, for a total value of $45,000.00. Following the completion of the transaction, the vice president now owns 120,000 shares in the company, valued at approximately $1,800,000. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Dean Slagel sold 250,000 shares of Cara Therapeutics stock in a transaction dated Thursday, June 29th. The shares were sold at an average price of $25.87, for a total value of $6,467,500.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 278,000 shares of company stock valued at $6,888,750. 7.70% of the stock is owned by company insiders.
ILLEGAL ACTIVITY WARNING: This report was first reported by Daily Political and is the property of of Daily Political. If you are viewing this report on another domain, it was copied illegally and reposted in violation of U.S. & international copyright law. The correct version of this report can be accessed at https://www.dailypolitical.com/2017/09/24/cara-therapeutics-cara-earns-news-sentiment-rating-of-0-18.html.
Cara Therapeutics Company Profile
Cara Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body’s peripheral nervous system.
Receive News & Ratings for Cara Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.